Insulet Co. (NASDAQ:PODD) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Insulet Co. (NASDAQ:PODD) have been assigned an average recommendation of “Moderate Buy” from the eighteen analysts that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $239.18.

PODD has been the subject of several analyst reports. OTR Global restated a “mixed” rating on shares of Insulet in a research note on Monday, June 10th. Barclays cut their price objective on shares of Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a research report on Monday, May 13th. Redburn Atlantic began coverage on shares of Insulet in a report on Thursday, May 30th. They set a “buy” rating and a $235.00 target price on the stock. Raymond James cut their price target on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating for the company in a report on Friday, May 10th. Finally, Canaccord Genuity Group boosted their price target on shares of Insulet from $226.00 to $234.00 and gave the company a “buy” rating in a research report on Friday, May 10th.

Insider Buying and Selling

In other Insulet news, SVP Mark N. Field sold 1,500 shares of the stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $199.96, for a total transaction of $299,940.00. Following the transaction, the senior vice president now directly owns 12,875 shares in the company, valued at $2,574,485. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Mark N. Field sold 2,131 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $190.43, for a total value of $405,806.33. Following the completion of the sale, the senior vice president now owns 14,375 shares of the company’s stock, valued at approximately $2,737,431.25. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Mark N. Field sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $199.96, for a total value of $299,940.00. Following the transaction, the senior vice president now owns 12,875 shares in the company, valued at $2,574,485. The disclosure for this sale can be found here. Insiders sold 13,931 shares of company stock worth $2,636,286 in the last quarter. 0.47% of the stock is owned by insiders.

Institutional Trading of Insulet

A number of institutional investors have recently made changes to their positions in PODD. Capital Research Global Investors raised its holdings in Insulet by 19.7% during the 4th quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock valued at $2,056,255,000 after buying an additional 1,556,455 shares during the last quarter. Baillie Gifford & Co. bought a new position in shares of Insulet during the fourth quarter valued at about $263,144,000. Norges Bank bought a new position in shares of Insulet during the fourth quarter valued at about $227,655,000. Goldman Sachs Group Inc. boosted its holdings in shares of Insulet by 56.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 878,529 shares of the medical instruments supplier’s stock worth $190,623,000 after purchasing an additional 316,649 shares during the period. Finally, Canada Pension Plan Investment Board grew its stake in shares of Insulet by 206.9% in the first quarter. Canada Pension Plan Investment Board now owns 429,591 shares of the medical instruments supplier’s stock worth $73,632,000 after purchasing an additional 289,591 shares during the last quarter.

Insulet Stock Performance

Shares of PODD stock opened at $196.72 on Thursday. The firm’s 50 day moving average is $185.42 and its 200 day moving average is $186.27. The stock has a market capitalization of $13.78 billion, a P/E ratio of 59.61, a PEG ratio of 3.63 and a beta of 1.16. Insulet has a 12 month low of $125.82 and a 12 month high of $293.64. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.34. The firm had revenue of $441.70 million for the quarter, compared to the consensus estimate of $424.05 million. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The business’s quarterly revenue was up 23.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.23 earnings per share. On average, sell-side analysts anticipate that Insulet will post 3.11 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.